Session on Biotech & Pharmaceuticals 13 February 2017: 1400 – 1555 Hrs, Grand Ball Room, Hotel Lalit Ashok, Bengaluru

India is among the top 12 biotech destinations in the world and ranks third in Asia-Pacific region. India is expected to rank amongst the top three pharmaceutical markets in terms incremental growth by 2020. India’s generic drugs account for 20% of global exports in terms of volume, making the country the largest provider of generic medicines globally. Bengaluru has taken a leadership stance in the biotechnology revolution of the country. More than 50 percent of the Biotech firms are situated in Bengaluru which comprises of top 10 Biotech firms and shows promising growth. This session shall deliberate on the significance of R&D and Innovation in the Pharma and Biotech sector and showcasing Karnataka’s leadership position and vision for these two sectors.

1330 – 1400 Hrs

1400 – 1410 Hrs
Opening Remarks & Context Setting

Dr Krishna Ella
Managing Director
Bharat Biotech International

1410 – 1420 Hrs
Keynote Address

Kiran Mazumdar-Shaw

Chairman & Managing Director

Biocon Ltd

1420 – 1430 Hrs
Keynote Address

Annaswamy Vaidheesh
Managing Director
GSK Pharmaceuticals Ltd

1430 – 1520 Hrs

Signature Statement by Keynote Panelists

Moderated by: Dr P M Murali, Managing Director & CEO, Evolva Biotech Pvt. Ltd.

G S Krishnan

Country Head

Novozymes South Asia

Milind Palsule

Country Manager

GE Healthcare Lifesciences – South Asia

Vinay Konaje

Founder – Director
Navya Biologicals Pvt. Ltd.

Srini Srinivasan

Managing Director

Hospira Healthcare (I) Pvt. Ltd. (a Pfizer Company)

Dr Ravi Kumar

Founder & Director

Xcyton Diagnostics Ltd.

Dr KK Narayanan

Consultant Biotechnologist

Metahelix Life Sciences

Subramani Ramachandrappa

Chairman & Managing Director

Richcore Lifesciences


1520 – 1530 Hrs
Special Address

V Manjula, IAS

Additional Chief Secretary

Department of IT & BT and Science & Technology

Government of Karnataka

1530-1540 Hrs
Special Address

Sudhansh Pant, IAS

Joint Secretary

Department of Pharmaceuticals

Ministry of Chemicals & Fertilizers

Government f India

1540 – 1550 Hrs
Special Address

Dr T Madhan Mohan


Department of Biotechnology

Ministry of Science & Technology

Government of India

1550 – 1555 Hrs
Concluding Remarks

Dr Jagadish Mittur


Biotech Facilitation Centre

Government of Karnataka

1555 – 1600 Hrs

Session Changeover


The sector has seen high growth with a CAGR in excess of 20% and the key drivers for growth in the biotech sector are increasing investments, outsourcing activities, exports and the government's focus on the sector

New Investment opportunities in India are in the areas of:

Drug discovery and clinical trials

Medical devices manufacturing


Secondary agriculture

Who should attend?

The C-Suite leadership

Senior members of Plastics & Chemicals and Allid Industries

Heads of Verticals: R & D, Business & Strategy Potential Investors